

**Minutes of the June 6, 2014
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical Services**

Members Present

Richard Holm, MD; Bill Ladwig, RPh; Kelly Oehlke, PharmD; Dana Darger, RPh; Debra Farver, PharmD; Mikel Holland, MD; James Engelbrecht, MD

DSS staff present

Mike Jockheck, RPh; Ann Schwartz, Dep. Director of Medical Services; Kirby Stone, Director of Medical Services

Administrative Business

The P&T meeting was called to order by D. Darger at 1:00pm. The minutes of the March 21, 2014 meeting were presented. B. Ladwig made a motion to approve. R. Holm seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

The committee reviewed the prior authorization (PA) activity for April 2014. There were a total of 2,982 PA's processed in the month of April, with 99.70% of those requests responded to in less than eight hours. There were 2,287 (77%) requests received electronically and 695 (23%) requests received by fax.

Analysis of the top 15 Therapeutic Classes

The committee reviewed the Top 15 Therapeutic Classes by total cost of claims from 01/1/2014 – 03/31/2014. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, central nervous system agents, misc., and corticosteroids (respiratory tract). The top 15 therapeutic classes make up 40.23% of total claims. The Committee also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 10.65% of total claims.

Review of Drug Spend

The committee reviewed a table showing SD Medicaid drug spend from 2011 – 2013. The average cost per script rose from \$63.57 in 2011 to \$69.24 in 2013. The average recipient script cost rose from \$172.51 in 2011 to \$187.99 in 2013.

Patent Expirations

The committee reviewed a list of medications with an upcoming anticipated availability of a first-time generic.

Sovaldi and Olysio Second Review

The committee reviewed Olysio and Sovaldi prior authorization forms. The committee heard testimony from Paul Miner (Gilead) and Kathleen Karnik (Janssen). A motion was made by B. Ladwig to approve the Sovaldi and Olysio forms. D. Farver seconded the motion. The motion was approved unanimously. Utilization data will be brought to the September meeting for committee review.

Luzu Second Review

The committee made a motion at the March meeting to place Luzu on prior authorization. The form was brought back for committee approval. There was no public comment. A motion was made by B. Ladwig to approve the Luzu prior authorization form. K. Oehlke seconded the motion. The motion was approved unanimously.

Hetlioz Review

The committee made a motion at the March meeting to place Hetlioz on prior authorization. The form was brought back for committee approval. There was no public comment. A motion was made by D. Farver to approve the Hetlioz prior authorization form. K. Oehlke seconded the motion. The motion was approved unanimously.

Advair Utilization Review

At the March meeting, the committee requested Advair utilization be added to the June agenda. Utilization was reviewed.

Stimulant Use in Adults

At the March meeting, the committee requested stimulant use in adults be added to the June agenda. Utilization was reviewed. The committee requested that a list of the top 10-15 prescribers writing stimulants for adults be brought back to the next meeting.

Oral Allergen Extracts (Ragwitek, Grastek, Oralair)

The committee reviewed oral allergen extracts clinical information. There was no public comment. R. Holm made a motion to place oral allergen extracts on prior authorization for indication. K. Oehlke seconded the motion. The motion was approved unanimously. A prior authorization form will be developed and brought back to the September meeting for committee approval.

Northera Review

The committee reviewed Northera clinical information. There was no public comment. This topic was tabled.

The next meeting is scheduled for September 26, 2014. K. Oehlke made a motion to adjourn the P&T Committee meeting. D. Farver seconded the motion. The motion passed unanimously and the meeting was adjourned.